Incannex Healthcare Inc. Files SEC Form EFFECT – Quantisnow
Incannex Healthcare Inc., a company focusing on cannabinoid and psychedelic medicine, recently completed a pre-investigational new drug meeting with the FDA for their new treatment, CannQuit-O, designed to help with opioid use disorder. During this meeting, FDA representatives provided insights and recommendations for the clinical development strategy of CannQuit-O.
CannQuit-O is a chewable tablet that combines CBD with an off-patent prescription opioid antagonist and/or partial agonist-antagonist. This innovative formulation aims to address the challenges of opioid use disorder effectively and safely.
This achievement follows Incannex’s positive financial results and business update for the quarter ending on September 30, 2024. The company reported ongoing progress and growth in its development of novel oral synthetic cannabinoid combination therapeutics and oral synthetic psilocybin treatment. Incannex’s commitment to providing innovative medicines for chronic diseases is clearly showcased through their strategic partnerships and clinical advancements.
Moreover, Incannex recently appointed Dr. Lou Barbato as its Chief Medical Officer, bringing with him extensive drug development experience across several pharmaceutical companies. With this strengthening of their leadership team, Incannex continues to advance its clinical-stage programs in conditions like obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis.
The company received clearance from the FDA for Investigational New Drug applications, commenced dosing for specific clinical trials, and secured significant financing to support its research and development efforts. These milestones indicate Incannex’s dedication to improving patient care and addressing unmet medical needs through innovative pharmaceutical solutions.
In summary, Incannex Healthcare Inc. is making notable progress in developing groundbreaking treatments for a variety of health conditions, guided by a commitment to excellence and patient-centric care.
